证券之星价投圈财报分析工具显示：业务评价：公司去年的ROIC为23.16%，资本回报率极强。去年的 净利率为20.64%，算上全部成本后，公司产品或服务的附加值高。从历史年报数据统计来看，公司近 10年来中位数ROIC为13.95%，中位投资回报一般，其中最惨年份2015年的ROIC为6.9%，投资回报一 般。公司历史上的财报相对良好。商业模式：公司业绩主要依靠营销驱动。需要仔细研究这类驱动力背 后的实际情况。 财报体检工具显示：建议关注公司现金流状况(货币资金/流动负债仅为26.05%) 分析师工具显示：证券研究员普遍预期2025年业绩在8.37亿元，每股收益均值在1.48元。 该公司被1位明星基金经理持有，持有该公司的最受关注的基金经理是易方达基金的王元春，在2024年 的证星公募基金经理顶投榜中排名前五十，其现任基金总规模为8.93亿元，已累计从业6年257天，擅长 挖掘成长股。 据证券之星公开数据整理，近期羚锐制药(600285)发布2025年中报。截至本报告期末，公司营业总收入 20.99亿元，同比上升10.14%，归母净利润4.74亿元，同比上升14.85%。按单季度数据看，第二季度营 业总收入1 ...

Core Viewpoint - The financial performance of Shuangle Co., Ltd. (301036) for the first half of 2025 shows a significant decline in revenue and profit compared to the previous year, indicating potential challenges in the company's operations and financial health [1]. Financial Performance Summary - Total revenue for the first half of 2025 was 748 million yuan, a decrease of 8.44% year-on-year [1]. - Net profit attributable to shareholders was 44.76 million yuan, down 32.95% year-on-year [1]. - In Q2 2025, total revenue was 362 million yuan, reflecting a 20.12% decline year-on-year, while net profit was 22.87 million yuan, a decrease of 52.5% [1]. - The gross margin was 15.89%, down 3.56% year-on-year, and the net margin was 5.98%, down 26.77% year-on-year [1]. - Total expenses (selling, administrative, and financial) amounted to 32.11 million yuan, representing 4.29% of revenue, an increase of 20.84% year-on-year [1]. - Earnings per share decreased to 0.45 yuan, down 32.84% year-on-year, and operating cash flow per share was -0.2 yuan, a decline of 118.3% [1]. Balance Sheet and Cash Flow Summary - Cash and cash equivalents decreased by 53.82% due to reduced bank deposits and discounting of bank bills [3]. - Inventory increased by 4.81% due to a rise in stock of goods [3]. - Construction in progress decreased by 57.06% as projects were completed [4]. - Contract liabilities increased by 38.3% due to higher prepayments from customers [4]. - Accounts receivable financing rose by 76.1% due to an increase in bank acceptance bills [4]. - Other receivables surged by 235.62%, indicating a rise in miscellaneous receivables [4]. - The net cash flow from operating activities decreased by 118.3%, attributed to reduced cash receipts from sales [6]. Operational Insights - The company's return on invested capital (ROIC) was 7.59%, indicating average capital returns, with a historical median ROIC of 8.36% since its listing [6]. - The net profit margin for the previous year was 7.66%, suggesting average value addition from products or services [6]. - The accounts receivable to net profit ratio reached 212.88%, highlighting potential liquidity concerns [7].

Group 1 - The company reported a total operating revenue of 908 million yuan for the first half of 2025 [1] - The net profit attributable to shareholders reached 69.02 million yuan, an increase of 39.54 million yuan compared to the same period last year, representing a year-on-year growth of 134.13% [1] - The net cash inflow from operating activities was 150 million yuan [1] Group 2 - The latest debt-to-asset ratio of the company is 49.72% [3] - The gross profit margin improved to 19.41%, an increase of 1.69 percentage points compared to the same period last year [3] - The return on equity (ROE) is 2.12%, up by 1.24 percentage points year-on-year [3] Group 3 - The diluted earnings per share (EPS) is 0.18 yuan, an increase of 0.11 yuan compared to the same period last year, reflecting a year-on-year rise of 145.33% [3] - The total asset turnover ratio is 0.14 times [3] - The inventory turnover ratio is 0.57 times [3] Group 4 - The number of shareholders is 33,400, with the top ten shareholders holding a total of 176 million shares, accounting for 44.75% of the total share capital [3] - The top shareholder is Tao Shi, holding 28.0 million shares [3] - Other notable shareholders include Tian De with 7.92 million shares and the first employee stock ownership plan with 2.29 million shares [3]

2025年8月16日，思源电气(002028.SZ)发布2025年中报。 公司营业总收入为84.97亿元，较去年同报告期营业总收入增加23.31亿元，实现5年连续上涨，同比较去年同期上涨37.80%。归母净利润为12.93亿元，较去 年同报告期归母净利润增加4.06亿元，实现3年连续上涨，同比较去年同期上涨45.71%。经营活动现金净流入为-7.13亿元。 公司最新资产负债率为46.13%。 公司最新毛利率为31.74%，较上季度毛利率增加1.42个百分点。最新ROE为9.66%，较去年同期ROE增加1.63个百分点。 公司摊薄每股收益为1.66元，较去年同报告期摊薄每股收益增加0.51元，实现3年连续上涨，同比较去年同期上涨44.35%。 公司最新总资产周转率为0.35次，较去年同期总资产周转率增加0.03次，同比较去年同期上涨8.53%。最新存货周转率为1.42次，较去年同期存货周转率增加 0.07次，同比较去年同期上涨5.41%。 公司股东户数为2.00万户，前十大股东持股数量为4.64亿股，占总股本比例为59.58%，前十大股东持股情况如下： | 序号 | 股东名称 | 持股 | | --- | -- ...

Core Viewpoint - The company reported a steady growth in revenue and net profit for the first half of 2025, indicating a positive financial trend over the past five years [1][3]. Financial Performance - The company's total revenue for the first half of 2025 was 372 million yuan, an increase of 4.96 million yuan compared to the same period last year, marking a year-on-year growth of 1.35% [1]. - The net profit attributable to shareholders was 95.01 million yuan, up by 2.23 million yuan from the previous year, reflecting a year-on-year increase of 2.40% [1]. - Operating cash flow was reported at 61.70 million yuan [1]. Profitability Metrics - The latest gross profit margin stood at 60.68%, an increase of 1.06 percentage points from the previous quarter and up by 1.42 percentage points year-on-year [3]. - The return on equity (ROE) was recorded at 6.35% [3]. Efficiency Ratios - The diluted earnings per share were 0.43 yuan [4]. - The total asset turnover ratio was 0.18 times, remaining stable compared to the same period last year, with a slight increase of 1.17% [4]. - The inventory turnover ratio improved to 3.17 times, an increase of 0.26 times year-on-year, representing a growth of 9.02% [4]. Shareholder Structure - The number of shareholders was reported at 17,800, with the top ten shareholders holding a total of 125 million shares, accounting for 54.53% of the total share capital [4]. - The largest shareholder, 吕杰中, holds 17.79% of the shares, followed by NH 吕保忠 with 14.18% and 高諾 3 4 李生平 with 12.48% [4].

2025年8月16日，昆药集团(600422.SH)发布2025年中报。 公司营业总收入为33.51亿元，较去年同报告期营业总收入减少4.43亿元，同比较去年同期下降 11.68%。归母净利润为1.98亿元，较去年同报告期归母净利润减少7291.02万元，同比较去年同期下降 26.88%。经营活动现金净流入为2.19亿元，较去年同报告期经营活动现金净流入减少6243.51万元，同 比较去年同期下降22.20%。 公司摊薄每股收益为0.26元，较去年同报告期摊薄每股收益减少0.10元，同比较去年同期下降27.78%。 公司最新总资产周转率为0.27次，较去年同期总资产周转率减少0.05次，同比较去年同期下降16.57%。 最新存货周转率为1.34次，较去年同期存货周转率增加0.16次，同比较去年同期上涨13.82%。 公司股东户数为3.94万户，前十大股东持股数量为3.58亿股，占总股本比例为47.33%，前十大股东持股 情况如下： | 序号 | 股东名称 | 持股比例 | | --- | --- | --- | | I | 华润三九医药股份有限公司 | 28.05% | | 2 | 云南合和(集团)股份有限公 ...

2025年8月16日，民丰特纸(600235.SH)发布2025年中报。 公司最新资产负债率为50.06%，较上季度资产负债率减少0.63个百分点，较去年同期资产负债率增加 3.64个百分点。 公司最新毛利率为16.89%，较上季度毛利率增加0.68个百分点，较去年同期毛利率增加1.64个百分点， 实现2年连续上涨。最新ROE为1.00%，较去年同期ROE减少2.25个百分点。 公司摊薄每股收益为0.04元，较去年同报告期摊薄每股收益减少0.10元，同比较去年同期下降68.84%。 公司营业总收入为6.01亿元，较去年同报告期营业总收入减少1.82亿元，同比较去年同期下降23.21%。 归母净利润为1507.37万元，较去年同报告期归母净利润减少3335.76万元，同比较去年同期下降 68.88%。经营活动现金净流入为1645.99万元，较去年同报告期经营活动现金净流入减少1.03亿元，同 比较去年同期下降86.20%。 公司最新总资产周转率为0.20次，较去年同期总资产周转率减少0.10次，同比较去年同期下降34.40%。 最新存货周转率为1.35次，较去年同期存货周转率减少0.27次，同比较去年同期下降1 ...

Core Insights - The company reported a total revenue of 2.67 billion yuan for the first half of 2025, marking an increase of 275 million yuan and a year-on-year growth of 11.51% [1] - The net profit attributable to shareholders was -840 million yuan, an improvement of 439 million yuan compared to the same period last year [1] - The net cash inflow from operating activities was 233 million yuan, up 208 million yuan year-on-year, reflecting a significant increase of 855.77% [1] Financial Metrics - The latest debt-to-asset ratio stands at 66.92% [3] - The gross profit margin is -9.97%, which is an increase of 3.20 percentage points from the previous quarter and an increase of 16.99 percentage points year-on-year [3] - The return on equity (ROE) is -9.13%, showing an improvement of 2.20 percentage points compared to the same period last year [3] Earnings and Turnover - The diluted earnings per share are -0.06 yuan, an increase of 0.03 yuan from the same period last year [4] - The total asset turnover ratio is 0.09 times, which is an increase of 0.01 times year-on-year, reflecting a growth of 10.83% [4] - The inventory turnover ratio is 3.00 times [4] Shareholder Structure - The number of shareholders is 116,700, with the top ten shareholders holding 10.89 billion shares, accounting for 78.87% of the total share capital [4] - The largest shareholder is Shanghai Lianhe Investment Co., Ltd., holding 58.35% of the shares [4]

Core Insights - The company reported a total operating revenue of 795 million yuan, an increase of 106 million yuan compared to the same period last year, achieving a year-on-year growth of 15.42% [1] - The net profit attributable to shareholders reached 43.91 million yuan, up by 18.33 million yuan from the same period last year, marking a year-on-year increase of 71.68% [1] - The company experienced a negative net cash flow from operating activities of 136 million yuan [1] Financial Metrics - The latest debt-to-asset ratio stands at 44.68%, a decrease of 0.49 percentage points from the same period last year [3] - The gross profit margin is reported at 22.86%, an increase of 0.94 percentage points from the previous quarter [3] - The return on equity (ROE) is 1.78%, which is an increase of 0.67 percentage points compared to the same period last year [3] - The diluted earnings per share (EPS) is 0.03 yuan, an increase of 0.01 yuan from the same period last year, reflecting a year-on-year growth of 72.22% [3] - The total asset turnover ratio is 0.17 times, an increase of 0.02 times from the same period last year, achieving a year-on-year growth of 10.88% [3] - The inventory turnover ratio is reported at 0.81 times [3] Shareholder Structure - The number of shareholders is 64,000, with the top ten shareholders holding a total of 588 million shares, accounting for 41.54% of the total share capital [3] - The largest shareholder is Zhuzhou State-owned Assets Investment Holding Group Co., Ltd., holding 24.77% of the shares [3] - Other significant shareholders include CRRC Industry Investment Co., Ltd. (5.00%) and Chalco International Engineering Co., Ltd. (3.80%) [3]

Core Insights - The company BGI Genomics (301269.SZ) reported a total operating revenue of 502 million yuan for the first half of 2025, an increase of 57.75 million yuan compared to the same period last year, marking a 13.01% year-on-year growth [1] - The net profit attributable to shareholders was 3.07 million yuan, a decrease of 34.80 million yuan from the same period last year, representing a 91.90% decline [1] - The net cash inflow from operating activities was 243 million yuan, an increase of 249 million yuan compared to the same period last year [1] Financial Ratios - The latest debt-to-asset ratio is 8.11%, which is an increase of 0.39 percentage points from the previous quarter but a decrease of 1.67 percentage points from the same period last year [3] - The latest gross profit margin is 89.12%, down 2.29 percentage points from the previous quarter and down 2.27 percentage points from the same period last year [3] - The latest return on equity (ROE) is 0.06%, a decrease of 0.72 percentage points from the same period last year [3] Earnings and Turnover - The diluted earnings per share are 0.01 yuan, a decrease of 0.06 yuan compared to the same period last year, reflecting a 91.83% decline [4] - The latest total asset turnover ratio is 0.09 times, an increase of 0.01 times from the same period last year, marking a 10.93% year-on-year growth [4] - The latest inventory turnover ratio is 0.91 times, an increase of 0.13 times from the same period last year, representing a 16.44% year-on-year increase [4] Shareholder Structure - The number of shareholders is 37,800, with the top ten shareholders holding 436 million shares, accounting for 80.34% of the total share capital [4] - The largest shareholder is China Electronics Corporation, holding 21.22% of the shares [4] - Other significant shareholders include Beijing Jiuchuang Huixin Asset Management Partnership (17.63%) and China Electronics Investment Holdings (12.84%) [4]